Metastatic Colorectal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...
Bicara Therapeutics announces first patients dosed in FORTIFI-HN01 trial
Bicara Therapeutics (BCAX) announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in ...
The American Journal of Managed Care6h
Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...
oncnursingnews7h
Pembrolizumab Shows ORR, Tolerability in Previously Treated Gynecologic Cancer
Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...
Armed robbery in Revesby9h
Pfizer, Astellas' PADCEV Plus KEYTRUDA Shows Efficacy
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...
Targeted Oncology12h
Seeking Optimal Combinations and Treatment Sequencing in Cervical Cancer
Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...
The American Journal of Managed Care13h
Changes in Tumor Size Track Advanced RCC Outcomes, Analyses From CLEAR Show
Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...